Teva Pharmaceutical Industries (TEVA) Cash & Equivalents (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Cash & Equivalents came in at $3.7 billion in Q2 2026, up 69.13% YoY from $2.2 billion in Q2 2025, and down 2.3% on a QoQ basis from $3.7 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Cash & Equivalents (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Cash & Equivalents data on file, last reported at $3.7 billion in Q2 2026.
- Quarterly Cash & Equivalents rose 69.13% year-over-year to $3.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.7 billion (up 69.13% YoY) and the FY2025 annual result came in at $3.6 billion, up 7.76% from the prior year.
- Cash & Equivalents fell to $3.7 billion in Q2 2026, from $3.7 billion in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $3.7 billion in Q1 2026 to a low of $1.7 billion in Q1 2025.
- A 5-year average of $2.7 billion and a median of $2.5 billion in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2025 — Cash & Equivalents plunged 43.26% — and 2026, when it jumped 120.45%.
- Tracing TEVA's Cash & Equivalents over 5 years: stood at $2.8 billion in 2022, then climbed by 15.17% to $3.2 billion in 2023, then gained by 2.29% to $3.3 billion in 2024, then rose by 7.76% to $3.6 billion in 2025, then grew by 2.78% to $3.7 billion in 2026.
- The last three Cash & Equivalents figures came in at $3.7 billion (Q2 2026), $3.7 billion (Q1 2026), and $3.6 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 164.00 Mn |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 511.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.66 Bn |
| Mar 31, 2026 | 3.74 Bn |
| Dec 31, 2025 | 3.56 Bn |
| Sep 30, 2025 | 2.20 Bn |
| Jun 30, 2025 | 2.16 Bn |
| Mar 31, 2025 | 1.70 Bn |
| Dec 31, 2024 | 3.30 Bn |
| Sep 30, 2024 | 3.32 Bn |
| Jun 30, 2024 | 2.26 Bn |
| Mar 31, 2024 | 2.99 Bn |
| Dec 31, 2023 | 3.23 Bn |
| Sep 30, 2023 | 2.25 Bn |
| Jun 30, 2023 | 2.67 Bn |
| Mar 31, 2023 | 2.14 Bn |
| Dec 31, 2022 | 2.80 Bn |
| Sep 30, 2022 | 2.23 Bn |
| Jun 30, 2022 | 2.06 Bn |
| Mar 31, 2022 | 2.18 Bn |
| Dec 31, 2021 | 2.17 Bn |
| Sep 30, 2021 | 2.05 Bn |